8-K: Strata Critical Medical Acquires Keystone Perfusion for $124M

Strata Critical Medical, Inc. has completed the acquisition of Keystone Perfusion Services, LLC for $124 million, creating an integrated organ recovery platform and diversifying into other critical medical services.

Summary

• Strata Critical Medical, Inc. (SRTA) acquired Keystone Perfusion Services, LLC for an aggregate consideration of $124 million, with potential earn-outs up to an additional $23 million.
• The upfront consideration was paid approximately 88% in cash and 12% in Strata common stock.
• Keystone is a leading provider of organ recovery and normothermic regional perfusion (NRP) services to the transplant industry, also offering perfusion and critical medical solutions for non-transplant surgeries.
• The acquisition creates the only full-service organ transplant service provider offering surgical recovery, NRP, air and ground logistics, and organ placement services.
• Keystone's non-transplant services represent a new addressable market opportunity for Strata, expected to account for over half of Keystone's revenue.
• Keystone's CEO, Louis Verdetto, and key management, Michael Hancock and Christie Campbell, will remain in their roles and are eligible for earn-out payments through 2028.
• Strata issued 3,434,607 common shares as part of the consideration, relying on an exemption from registration.

Sentiment

Score: 8

Explanation: The acquisition is highly strategic, creating a unique market position and significantly boosting Strata's revenue and EBITDA projections with a high-growth, high-cash-flow business. The retention of key management and the earn-out structure are positive. While the valuation multiple is notable and integration risks exist, the overall outlook presented is very strong for future growth and market leadership.

Positives

• The acquisition creates the only full-service organ transplant service provider, integrating surgical recovery, NRP, logistics, and organ placement.
• The transaction diversifies Strata's business into non-transplant medical services, which are expected to represent over half of Keystone's revenue.
• Keystone is projected to generate approximately $65 million in revenue and $13 million in Adjusted EBITDA for the full year 2025, with revenue growth exceeding 50% compared to 2024.
• Keystone's go-forward Free Cash Flow conversion is expected to be approximately 80%, indicating strong operational efficiency.
• Key Keystone management (Louis Verdetto, Michael Hancock, Christie Campbell) will remain with the company, ensuring continuity and expertise.
• The earn-out structure incentivizes Keystone management to achieve significant gross profit growth targets through 2028.
• The acquisition leverages a multi-year successful partnership between Strata and Keystone, indicating a strong operational fit and proven collaboration.

Negatives

• The acquisition involves a significant upfront consideration of $124 million, plus potential earn-outs up to $23 million, which could strain financial resources if not managed effectively.
• The stock consideration issued is subject to a minimum four-year lock-up, extended to seven years if Keystone management does not remain employed for three years, which could impact liquidity for those recipients.
• The purchase price represents an approximate 9x multiple of 2025 estimated Adjusted EBITDA, which is a relatively high valuation.
• The forward-looking Adjusted EBITDA and Free Cash Flow guidance are not reconciled to GAAP measures due to variability and low visibility of certain costs, making precise financial comparison difficult.
• The filing highlights risks such as unexpected costs, failure to realize anticipated benefits, and continued incurrence of significant losses, which could negatively impact the combined entity.

Risks

• Unexpected costs, charges, or expenses resulting from the recently completed divestiture of Strata's passenger business.
• Failure to realize the anticipated efficiencies and benefits of the acquisition of Keystone.
• Continued incurrence of significant losses by Strata.
• Failure of the markets for Strata's offerings to grow as expected, or at all.
• Challenges in successfully entering new markets and launching new routes and services.
• Adverse publicity stemming from accidents involving small aircraft, helicopters, or charter flights, particularly those involving third-party operators.
• Impact of the recently completed sale of the passenger business, any change to the ownership of Strata's aircraft, and related challenges.
• Effects of competition, harm to Strata's reputation and brand.
• Ability to provide high-quality customer support and maintain a high daily aircraft usage rate.
• Changes in economic conditions, impact of natural disasters, outbreaks, pandemics, economic, social, weather, geopolitical, growth constraints, and regulatory conditions in areas of geographic concentration.
• Effects of climate change, including potential increased impacts of severe weather and regulatory activity.
• Availability of aircraft fuel.
• Ability to address system failures, defects, errors, or vulnerabilities in Strata's or third-party technology systems.
• Interruptions or security breaches of information technology systems.
• Ability to protect intellectual property rights and risks associated with open source software use.
• Ability to expand and maintain infrastructure network and access additional funding.
• Ability to identify, complete, and successfully integrate future acquisitions and manage growth.
• Increases in insurance costs or reductions in insurance coverage.
• Loss of key members of the management team.
• Ability to maintain company culture.
• Reliance on contractual relationships with certain transplant centers and Organ Procurement Organizations.
• Effects of fluctuating financial results and reliance on third-party operators.
• Changes in the regulatory environment and risks/impact of any litigation.
• Regulatory obstacles in local governments and expansion of domestic and foreign privacy and security laws and environmental regulations.
• Ability to remediate any material weaknesses or maintain internal controls over financial reporting.
• Changes in the fair value of warrants.
• The effect of the acquisition announcement on business relationships, operating results, and business generally.
• Unexpected costs, charges, or expenses resulting from the acquisition.

Future Outlook

Strata expects the Keystone acquisition to significantly enhance its financial performance, with updated 2025 revenue guidance of $180-$190 million and Adjusted EBITDA of $13-$14 million (reflecting post-closing impact). On a pro forma basis, assuming the acquisition closed on January 1, 2025, Strata projects 2025 revenue of $225-$235 million and Adjusted EBITDA of $22-$24 million. The company anticipates providing 2026 guidance at its investor day in November 2025, inclusive of the acquisition's impact. The acquisition is expected to open new addressable markets in fragmented medical sectors with significant organic and inorganic growth opportunities.

Management Comments

• "Having partnered with Lou, Mike, Christie and the entire Keystone team for hundreds of successful organ recoveries using NRP, we've had a front-row seat to their unmatched skill coupled with leading tech-enabled communication and quality control." Will Heyburn, Co-CEO of Strata.
• "Like our acquisition of Trinity, this opportunity was born out of the mutual respect and trust we built through a successful commercial relationship, giving us the first-hand experience we need to offer Keystone's services to our nationwide customer base with absolute confidence." Will Heyburn, Co-CEO of Strata.
• "Keystone's NRP and recovery services enable us to say yes to our transplant customers' requests to provide these additional critical services directly, which we have historically arranged for them through third-parties." Melissa Tomkiel, Co-CEO of Strata.
• "At the same time, we're establishing a platform to provide non-transplant-related solutions to new healthcare customers, a core tenet of our growth strategy following the divestiture of our passenger business, with such services representing more than half of Keystone's revenue." Melissa Tomkiel, Co-CEO of Strata.
• "The non-transplant services provided by Keystone represent a new addressable market opportunity for Strata in fragmented medical sectors with significant organic and inorganic growth opportunities." Melissa Tomkiel, Co-CEO of Strata.
• "Clients are seeking a trusted partner that not only delivers clinical expertise and exceptional service but a comprehensive solution encompassing rapidly deployable surgical and perfusion teams, equipment, logistics support, disposables, and critical transportation." Louis Verdetto, CEO of Keystone Perfusion.
• "By joining Strata, Keystone becomes part of a platform built to do exactly that—across transplant services, perfusionist staffing for cardiac surgery, and the broader hospital sector." Louis Verdetto, CEO of Keystone Perfusion.
• "Our customers will see continuity in the people and services they already rely on, with the added benefit of broader infrastructure, advanced logistics, and integrated transportation capabilities that not only ensure every case runs seamlessly from recovery to delivery, but also create meaningful efficiencies and growth opportunities as we scale nationally." Louis Verdetto, CEO of Keystone Perfusion.

Industry Context

The acquisition positions Strata Critical Medical as a unique, full-service provider in the organ transplant logistics and medical services sector. This move aligns with a broader trend in healthcare towards integrated solutions and specialized services, particularly in high-stakes areas like organ transplantation where efficiency and expertise are paramount. By combining logistics with critical medical services like NRP and surgical recovery, Strata is addressing a market need for streamlined, comprehensive support, potentially gaining a competitive advantage over fragmented service providers. The diversification into non-transplant medical solutions also reflects a strategy to tap into broader healthcare market opportunities beyond its core transplant logistics.

Comparison to Industry Standards

• The filing states that the acquisition "creates the only full-service organ transplant service provider offering surgical recovery, NRP services, air and ground logistics and organ placement services." This implies a unique market position rather than a direct comparison to existing competitors offering a full suite of these specific services.
• Keystone is described as "one of the largest organ recovery and normothermic regional perfusion ("NRP") service providers" and an "industry leader in perfusion and other critical medical solutions." This suggests Keystone itself is a benchmark in its niche.
• The acquisition multiple of approximately 9x 2025 estimated Adjusted EBITDA for Keystone is a key valuation metric. For a high-growth, specialized healthcare service provider, this multiple could be considered reasonable, though direct comparable transactions in this niche are not provided.
• Keystone's expected revenue growth of "more than 50% in 2025 versus 2024" and Free Cash Flow conversion of "approximately 80%" indicate strong operational performance and efficiency, which would generally be considered above average for many industries.

Management Changes

Corporate Governance

Legal Proceedings

• No specific new legal proceedings are mentioned as pending or threatened. The filing includes general risk factors related to litigation that could affect the company.

Related Party Transactions

• The Purchase and Sale Agreement details the acquisition of Keystone Perfusion Services, LLC by Strata Critical Medical, Inc. from LRV Holdco, Inc. and its owners (Louis Verdetto Irrevocable Trust, Louis Verdetto), which is the core transaction.
• As part of the purchase price distribution, amounts due to the Seller (cash or stock) will be paid to Michael Hancock and Christie Campbell, in addition to Louis Verdetto, according to specified allocation percentages, through Keystone's regular payroll procedures for these individuals, who are remaining employees.

Stakeholder Impact

• **Shareholders**: Potential for significant growth and diversification, but also dilution from stock issuance and exposure to integration risks. The lock-up on stock consideration for Keystone management aligns long-term interests.
• **Employees**: Key Keystone management (Louis Verdetto, Michael Hancock, Christie Campbell) will remain, ensuring continuity. Offers of employment were extended to "Specified Employees."
• **Customers**: Expected to benefit from continuity in services, broader infrastructure, advanced logistics, and integrated transportation capabilities, ensuring seamless operations from organ recovery to delivery.
• **Suppliers**: No specific impact on suppliers is mentioned, but the integration could lead to changes in supplier relationships over time.
• **Creditors**: The acquisition involves repayment of existing indebtedness of Keystone at closing, and Strata will replace L. Verdetto as guarantor for a lease agreement, potentially improving Keystone's credit profile under Strata's ownership.

Next Steps

• Strata will file financial statements and pro forma financial information required by Item 9.01 of Form 8-K within 71 days after the filing date.
• Strata plans to provide 2026 guidance, inclusive of the Keystone acquisition, at its investor day scheduled for Monday, November 17, 2025, in New York City.
• Buyer will prepare and deliver a preliminary post-closing price adjustment statement within 60 days after the Closing Date.
• Buyer will deliver monthly unaudited profit and loss statements for Keystone to Seller, starting November 30, 2025.
• Buyer or an Affiliate will use commercially reasonable efforts to replace L. Verdetto as guarantor of Keystone's obligations under a Lease Agreement dated April 22, 2025.

Key Dates

Recommendation

The acquisition of Keystone Perfusion is a highly strategic move for Strata Critical Medical, transforming it into a unique, full-service provider in the critical organ transplant and medical services sector. Keystone brings significant revenue and Adjusted EBITDA, with strong growth projections and high free cash flow conversion, which is expected to be immediately accretive to Strata's financial performance. The retention of key management and the earn-out structure align incentives for continued growth. While the valuation multiple is notable, the strategic diversification into new, fragmented medical markets and the creation of an integrated platform suggest substantial long-term value creation potential. The risks outlined are typical for acquisitions and forward-looking statements, but the strategic benefits and financial projections outweigh these concerns, making this a compelling growth opportunity.

Keywords

Strata Critical Medical, Keystone Perfusion, Acquisition, Organ Recovery, Normothermic Regional Perfusion, NRP, Transplant Industry, Medical Services, Healthcare Logistics, Adjusted EBITDA, SRTA, Merger, Healthcare, Perfusion Services, Strategic Growth